UM1

ACTG Presents Study at CROI Demonstrating Efficacy of Long-Acting Injectable Treatment Among People Who Had Previously Been Unable to Maintain Viral Suppression on Daily Oral Medication

Retrieved on: 
Wednesday, March 6, 2024
Infection, Chair, Bangladesh Technical Education Board, Mental health, Injection (medicine), University of Alabama, Rilpivirine, Fungal infection, NIAID, Arm, CROI, PWH, Quality of life, ACTG, Johnson & Johnson, Data monitoring committee, Conference, Health, University, ART, UM1, Male, DSMB, ViiV Healthcare, HIV, Failure, University of North Carolina, Vaccine

“ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

Key Points: 
  • “ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.
  • Participants received incentives and support to adhere to their daily oral medication to first achieve viral suppression and if successful, they were randomized to either receive long-acting injectable treatment every four weeks or continue taking daily oral medication.
  • The long-acting injectable treatment was more effective than the daily oral medication at maintaining virologic suppression and avoiding treatment-related discontinuation.
  • Twenty-eight participants receiving the long-acting injectable treatment experienced regimen failure (defined as virologic failure or treatment discontinuation), compared to 47 receiving daily oral medication.

ACTG CROI Presentation Demonstrates Superiority of HepB-CpG Vaccine Over Conventional Hepatitis B Vaccine Among People Living With HIV Who Have Not Previously Responded to Vaccination

Retrieved on: 
Wednesday, March 6, 2024
Infection, Bangladesh Technical Education Board, CD4, Superior, Hepatitis B, Headache, CpG, Fungal infection, NIAID, CROI, ACTG, University of Cincinnati, Weill Cornell Medicine, Conference, Vaccination, University, ART, Fatigue, Virus, Myalgia, White, Black, Protocol, UM1, Massachusetts General Hospital, Male, Hepatitis, HIV, University of North Carolina, Vaccine

These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.

Key Points: 
  • These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.
  • People living with HIV, especially those with lower CD4 counts, often do not develop protective antibodies after receiving conventional hepatitis B vaccines.
  • The HepB-CpG (HEPLISAV-B®) vaccine includes a TLR-9 agonist adjuvant (CpG 1018® adjuvant) and is known to achieve high protection against hepatitis B among people living with HIV, but until now there have been limited data about its protection among people living with HIV who have not responded to conventional hepatitis B vaccines.
  • “Hepatitis B remains a significant issue for people living with HIV, as having both viruses increases the likelihood of liver complications,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

ACTG CROI Presentations Show That Semaglutide Improves Metabolic-Associated Steatotic Liver Disease Among People Living With HIV

Retrieved on: 
Tuesday, March 5, 2024
Infection, Liver, Bangladesh Technical Education Board, Metabolism, Woman, P.T, Fungal infection, NIAID, Prediabetes, CROI, Liver injury, Inflammation, Quality of life, ACTG, ALT, Weight loss, Waist, Weight, Organ dysfunction, University of Southern California, Conference, Health, Glucagon-like peptide-1 receptor, University, SLIM, ART, Triglyceride, BMI, UM1, Insulin resistance, HIV, Non-alcoholic fatty liver disease, Research, University of North Carolina, Dietary supplement

Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented.

Key Points: 
  • Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented.
  • Together, these presentations demonstrate that semaglutide was highly effective in improving, and in some cases, resolving completely, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease) among people living with HIV.
  • SLIM LIVER is the first study evaluating semaglutide as a treatment for MASLD among people living with HIV.
  • MASLD is common among people living with HIV and likely acts synergistically with HIV to accelerate liver injury and organ dysfunction.

ACTG Presents Study at CROI Elucidating Mechanism of CMV on Aging-Related Pathways in HIV

Retrieved on: 
Monday, March 4, 2024
Infection, Chairperson, Bangladesh Technical Education Board, Diabetes, CMV, Metabolism, Merck, Cancer, Endothelial dysfunction, Fungal infection, NIAID, CROI, Inflammation, Blood, IL-6, Ageing, ACTG, Splenic infarction, Risk, Conference, Cytomegalovirus, University, ART, Biomarker, Merck & Co., University of California, UM1, Insulin resistance, Poster, Letermovir, Probability, Atherosclerosis, Plasma, TNF, HIV, University of North Carolina, Immune system, Brain

CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.

Key Points: 
  • CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.
  • Prior to the availability of effective antiretroviral therapy (ART) for HIV, CMV caused life-threatening infections in the eyes, brain, and gut in people with compromised immune systems due to advanced HIV.
  • “Investigators have found associations between CMV and heart disease, cancer, and other aging-related complications among people living with HIV,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair).

ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis Regimen Among People Living with HIV

Retrieved on: 
Wednesday, February 14, 2024
Infection, Bangladesh Technical Education Board, Tuberculosis, NIAID, Blood, Safety, ACTG, Trial of the century, TB, Risk, University, ART, Rifapentine, University of London, University of California, Johns Hopkins University, UM1, Pharmacokinetics, Diagnosis, Ageing, HIV, Research, University of North Carolina, Pharmaceutical industry

Previously, ACTG study A5349 demonstrated that a four-month, four-drug TB regimen that included high-dose rifapentine was as effective as the standard six-month regimen, cutting the treatment time by one third.

Key Points: 
  • Previously, ACTG study A5349 demonstrated that a four-month, four-drug TB regimen that included high-dose rifapentine was as effective as the standard six-month regimen, cutting the treatment time by one third.
  • “Understanding the relationship between these anti-TB and HIV medications is crucial, as an estimated one third of people living with HIV worldwide are at risk for developing TB,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • Dolutegravir is being supplied to study A5406 by ViiV Healthcare Ltd and the fixed-dose combination of dolutegravir/tenofovir disoproxil fumarate/lamivudine is being supplied by Viatris.
  • The ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice Chair).

ACTG Announces Launch of Clinical Trial Evaluating Novel Treatment for Tuberculous Meningitis

Retrieved on: 
Thursday, December 7, 2023
TBM, Infection, NIAID, Tuberculous meningitis, Research, Vanderbilt University, DRS, University of California, Mortality, Spinal cord, Ageing, Membrane, Brain, Pyrazinamide, Linezolid, UM1, Inflammation, University, HIV, Bangladesh Technical Education Board, Tuberculosis, University of North Carolina, ACTG, Rifampicin, Pharmaceutical industry

LOS ANGELES, Dec. 07, 2023 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the IMAGINE-TBM study (Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM, also known as A5384). IMAGINE-TBM is a phase 2, randomized, open-label trial comparing a six-month regimen of high-dose rifampicin, high-dose isoniazid, linezolid, and pyrazinamide to the nine-month standard-of-care regimen for the treatment of tuberculous meningitis.

Key Points: 
  • IMAGINE-TBM is a phase 2, randomized, open-label trial comparing a six-month regimen of high-dose rifampicin, high-dose isoniazid, linezolid, and pyrazinamide to the nine-month standard-of-care regimen for the treatment of tuberculous meningitis.
  • Tuberculous meningitis is a life-threatening infectious disease that causes inflammation of the membranes that surround the brain and spinal cord.
  • Even with standard-of-care treatment, outcomes are poor, with high rates of mortality and chronic disability among those who survive.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair).

Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor

Retrieved on: 
Tuesday, October 18, 2022
Other Health, Oncology, Technology, Hospitals, Artificial Intelligence, Genetics, Health Technology, Clinical Trials, Cardiology, Biotechnology, FDA, Health, LinkedIn, SMR, PI, P50, Weill Cornell Medical Center, Medicine, University, UPMC Hillman Cancer Center, EMA, SITC, Memorial, R01, ASCO, Drug development, FACP, Patient, UM1, Twitter, Immunotherapy, Inflammation, Internal medicine, Solution, Trial of the century, AACR, MD, Board, Large, Safety, University of Pittsburgh Medical Center, Associate, Melanoma, Radiation, UPMC, Director, Oncology, Clinical trial, Boston Medical Center, FDA, Empathy, Biomarker, Medical imaging, Pharmaceutical industry

physIQ announced today that Jason Luke, MD, FACP, a recognized expert in immuno-oncology, professor of medicine, and clinical practitioner has been appointed to the companys Medical Advisory Board.

Key Points: 
  • physIQ announced today that Jason Luke, MD, FACP, a recognized expert in immuno-oncology, professor of medicine, and clinical practitioner has been appointed to the companys Medical Advisory Board.
  • Dr. Luke brings extensive immuno-oncology expertise to physIQ that will provide immeasurable insight into our work on inflammation and oncology treatments, said Steve Steinhubl, MD, physIQs Chief Medical Officer.
  • Dr. Luke received his medical degree from Rosalind Franklin University of Medicine and Science/Chicago Medical School in North Chicago.
  • He completed an internship and residency in internal medicine at Boston University Medical Center and fellowships in medicine and medical oncology at Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York.

Finding HIV's Sweet Spot

Retrieved on: 
Tuesday, July 5, 2022
Cell, Memory, Wistar Institute, National, Media contacts database, Communication, University of California, San Francisco, Tcell, Roan, Protein, Tissue, AIDS, Biomarker, Infection, Population, UM1, Center, Blood, HIV, SAN, Bias, Fucose, CyTOF, Moore v. Regents of the University of California, Technology, University, Sugar, Antibody, Doctor of Philosophy, Virus, Urology, Cell biology, Gladstone Institutes, HIV/AIDS, Research, Severe acute respiratory syndrome coronavirus 2, HIV/AIDS research, Multimedia, Lectin, Collection, Vaccine, Pharmaceutical industry, Antibiotics, ELife, William Ewart Gladstone

SAN FRANCISCO, July 5, 2022 /PRNewswire/ -- HIV researchers have long been trying to identify the specific cells that the virus prefers to infect and hide in. They know that HIV favors a special type of immune cells called memory CD4 T cells. But these cells come in many flavors, and it has been difficult to ascertain exactly what makes one type of memory CD4 T cell more attractive to HIV than another.

Key Points: 
  • Together, the scientists uncovered surprisingly different sugar patterns on different immune cells, and an intriguing interplay between HIV and the sugars coating CD4 Tcells.
  • The work also showcases a new technique for studying individual cells from large populations that could lead to a more detailed picture of cellular diversity.
  • Encouraged by this finding, the scientists next applied CyTOF-Lec to CD4 Tcells that they had first exposed to HIV in the lab.
  • To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impactunsolved diseases.

New Braunfels Utility Deploys Sentient Energy’s UM1 Intelligent Line Sensors for Greater Underground Visibility

Retrieved on: 
Monday, May 23, 2022
Population, Overloading, Board of directors, Sentience, Solution, Comal Springs (Texas), Energy, City, Police, URD, NBU, UM1, Efficiency, Industry, Facebook, Trustee, Board, Safety, Maintenance, Visibility, LinkedIn, Twitter, Water, GLOBE, Renewable energy, Tunnel, Public utility

We are anticipating building on this success with the addition of Sentient Energys UM1 to our single phase underground residential distribution systems.

Key Points: 
  • We are anticipating building on this success with the addition of Sentient Energys UM1 to our single phase underground residential distribution systems.
  • Sentient Energys UM1 provides remote visibility, fault detection, and load monitoring in single-phase transformer cabinets.
  • Complete Overhead and Underground Fault Detection, Analytics and Visibility
    Sentient Energys Grid Analytics System consists of the MM3 and ZM1 overhead sensors, UM3+ and UM1 underground sensors, and the Ample Analytics Platform.
  • To learn more about how to improve undergrounding strategies by leveraging Sentient Energys UM1 intelligent sensors, read Enhance Visibility into Your Underground Power Lines with Intelligent Line Sensors https://www.sentientenergy.com/blog/enhance-visibility-into-your-undergr... on the Sentient Energy blog.

Sentient Energy Shapes the Market for Underground Line Sensors, Announces Industry-First Technology Advancements, and Customer Adoption

Retrieved on: 
Monday, May 23, 2022
Software, ROI, Investment, Energy, URD, UM1, Product management, LinkedIn, Twitter, GLOBE, Instrumentation, Renewable energy, Nightclub, Electrical wiring, Surveying

We've taken steps to definitively address previously unmet needs for intelligent underground line sensing technologies and shared expertise, said Bidesh Kar, Director of Product Management at Sentient Energy.

Key Points: 
  • We've taken steps to definitively address previously unmet needs for intelligent underground line sensing technologies and shared expertise, said Bidesh Kar, Director of Product Management at Sentient Energy.
  • Our innovative underground system visibility and data solutions facilitate substantial reductions in customer outage times.
  • New UM3+ Underground Line Sensor Platform Enhancements Set the Bar:
    The UM3+ underground intelligent line sensor monitors up to twelve phases of underground circuits to detect, analyze, and communicate faults and non-fault disturbances.
  • New Value Calculator Helps Utilities Assess Underground Line Sensor ROI:
    To help estimate the value of adding line sensors to underground distribution system feeders, Sentient Energy created a new online tool the Underground Line Sensing Value Calculator .